.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The IBCSG 23-01 trial evaluated whether women with breast cancer and sentinel-node micrometastases could safely avoid completion axillary lymph-node dissection. Long-term follow-up showed no clinically important disadvantage in disease-free or overall survival for patients managed without axillary dissection. The study became an important foundation for reducing the extent of axillary surgery in selected early breast cancers. Its relevance is broader than the specific population studied: it illustrates how better staging and effective systemic and radiation therapies can allow surgeons to remove less tissue without compromising outcomes. For contemporary breast practice, the decision remains dependent on disease extent, tumor characteristics and the total treatment plan, but the evidence strongly supports avoiding routine additional axillary surgery when only limited sentinel-node disease is present and the patient meets appropriate criteria. Reduced axillary intervention can improve quality of life by lowering risks of lymphoedema, sensory disturbance and shoulder dysfunction. The trial therefore supports a patient-centered approach to breast cancer surgery in which “more surgery” is not automatically equated with “better cancer care.”
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The IBCSG 23-01 trial evaluated whether women with breast cancer and sentinel-node micrometastases could safely avoid completion axillary lymph-node dissection. Long-term follow-up showed no clinically important disadvantage in disease-free or overall survival for patients managed without axillary dissection. The study became an important foundation for reducing the extent of axillary surgery in selected early breast cancers. Its relevance is broader than the specific population studied: it illustrates how better staging and effective systemic and radiation therapies can allow surgeons to remove less tissue without compromising outcomes. For contemporary breast practice, the decision remains dependent on disease extent, tumor characteristics and the total treatment plan, but the evidence strongly supports avoiding routine additional axillary surgery when only limited sentinel-node disease is present and the patient meets appropriate criteria. Reduced axillary intervention can improve quality of life by lowering risks of lymphoedema, sensory disturbance and shoulder dysfunction. The trial therefore supports a patient-centered approach to breast cancer surgery in which “more surgery” is not automatically equated with “better cancer care.”
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
